DigestRedComo funciona
Red
/
Empresas
En
No verificado

Enanta Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosSaludVIH, SIDA y enfermedades autoinmunes

45 Comunicados de prensa

Ver todos los comunicados de prensa
18/06/2026
Industria
Infancia
Biotecnología
Asistencia a la infancia
Salud
Sanidad
Farmacéutica
VIH, SIDA y enfermedades autoinmunes
Ir de compras
Medicina - Varios
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
28/05/2026
Web y redes sociales
Eventos
Ferias y Congresos
Biotecnología
VIH, SIDA y enfermedades autoinmunes
Salud
Farmacéutica
Medicina - Varios
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
11/05/2026
Eventos
Mercado de valores
Salud
Higiene alimentaria
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Farmacéutica
Biotecnología
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
04/05/2026
Web y redes sociales
Eventos
Ferias y Congresos
Industria
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
13/04/2026
Industria
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
07/04/2026
Eventos
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
30/03/2026
Eventos
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
03/03/2026
Web y redes sociales
Eventos
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
10/02/2026
Salud
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Sanidad
Medicina - Varios
Farmacéutica
Eventos
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
09/02/2026
Eventos
Mercado de valores
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Medicina - Varios
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Fuente
Enanta Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0